-
Je něco špatně v tomto záznamu ?
Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study
D. Frausová, Z. Hrušková, V. Lánská, J. Lachmanová, V. Tesař,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2003
BioMedCentral Open Access
od 2003
Directory of Open Access Journals
od 1999
Free Medical Journals
od 2003 do Před 6 měsíci
PubMed Central
od 2003
Europe PubMed Central
od 2003
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 1999-01-01
Open Access Digital Library
od 1999-10-01
Open Access Digital Library
od 1999-01-01
Open Access Digital Library
od 2003-01-01
Medline Complete (EBSCOhost)
od 2011-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2003
Springer Nature OA/Free Journals
od 1999-06-01
- MeSH
- ANCA-asociované vaskulitidy mortalita terapie MeSH
- čas MeSH
- dospělí MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- proporcionální rizikové modely MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výměna plazmy metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Plasma exchange (PLEX) has been used routinely for treatment of severe renal vasculitis and/or alveolar haemorrhage (AH) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the long-term benefit of PLEX in AAV remains unclear. We aimed to describe the characteristics and outcomes of patients treated with PLEX in a single centre. METHODS: Patients with AAV were identified by performing a case review of medical records of 705 patients who received PLEX in a single tertiary referral centre between 2000 and 2010. Patient characteristics and outcomes were recorded. The Kaplan-Meier method, log-rank tests and Cox regression analysis were used for survival analyses. RESULTS: A total of 94 patients with AAV were identified (44 men, 50 women; median age 60 years, range 21-90 years; 52 proteinase 3-ANCA, 41 myeloperoxidase-ANCA and 1 ANCA-negative; 8 double-positive for ANCA and anti-glomerular basement membrane; 93 newly diagnosed/1 relapse; 55 [58.5 %] required dialysis). The reasons for initiating PLEX therapy were severe renal involvement alone in 52 %, AH in 10 %, both renal involvement and AH in 35 %, and "other" in 3 %. The patients had 3-27 (median 7) PLEX sessions. At 3 months, 81 (86 %) of 94 were alive and 62 (66 %) of 94 were alive and dialysis-independent. The median follow-up was 41 months (minimum-maximum 0.5-137 months), when 56 (59.6 %) of 94 patients were alive and 47 (50 %) were dialysis-independent. The estimated overall survival rates were 75.3 % at 1 year and 61.1 % at 5 years. Patient survival decreased with increasing age at presentation (5-year survival 85 % for age <50 years, 64.4 % for ages 50-65 years, and 41 % for >65 years; p < 0.01 for comparison between all groups). Estimated renal survival rates were 65.5 % at 1 year and 43 % at 5 years. Renal survival was worse in patients aged >65 years than in the younger patients (5-year survival 25.1 % in patients >65 years vs. 50.8 % for those ≤65 years, p < 0.01). The estimated renal survival was better in patients with higher Disease Extent Index (DEI) >6 than in patients with DEI ≤6 (5-year survival 52.1 % vs. 39.4 %, p = 0.04), even though this was not confirmed in multivariate analysis. CONCLUSIONS: The mortality of patients presenting with severe manifestations of AAV remains high despite the use of PLEX. Older age at presentation is associated with worse overall and renal prognosis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017159
- 003
- CZ-PrNML
- 005
- 20241119085045.0
- 007
- ta
- 008
- 180515e20160713xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13075-016-1055-5 $2 doi
- 035 __
- $a (PubMed)27412443
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Frausová, Doubravka $u Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. doubravka.frausova@gmail.com. $7 xx0324610
- 245 10
- $a Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study / $c D. Frausová, Z. Hrušková, V. Lánská, J. Lachmanová, V. Tesař,
- 520 9_
- $a BACKGROUND: Plasma exchange (PLEX) has been used routinely for treatment of severe renal vasculitis and/or alveolar haemorrhage (AH) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the long-term benefit of PLEX in AAV remains unclear. We aimed to describe the characteristics and outcomes of patients treated with PLEX in a single centre. METHODS: Patients with AAV were identified by performing a case review of medical records of 705 patients who received PLEX in a single tertiary referral centre between 2000 and 2010. Patient characteristics and outcomes were recorded. The Kaplan-Meier method, log-rank tests and Cox regression analysis were used for survival analyses. RESULTS: A total of 94 patients with AAV were identified (44 men, 50 women; median age 60 years, range 21-90 years; 52 proteinase 3-ANCA, 41 myeloperoxidase-ANCA and 1 ANCA-negative; 8 double-positive for ANCA and anti-glomerular basement membrane; 93 newly diagnosed/1 relapse; 55 [58.5 %] required dialysis). The reasons for initiating PLEX therapy were severe renal involvement alone in 52 %, AH in 10 %, both renal involvement and AH in 35 %, and "other" in 3 %. The patients had 3-27 (median 7) PLEX sessions. At 3 months, 81 (86 %) of 94 were alive and 62 (66 %) of 94 were alive and dialysis-independent. The median follow-up was 41 months (minimum-maximum 0.5-137 months), when 56 (59.6 %) of 94 patients were alive and 47 (50 %) were dialysis-independent. The estimated overall survival rates were 75.3 % at 1 year and 61.1 % at 5 years. Patient survival decreased with increasing age at presentation (5-year survival 85 % for age <50 years, 64.4 % for ages 50-65 years, and 41 % for >65 years; p < 0.01 for comparison between all groups). Estimated renal survival rates were 65.5 % at 1 year and 43 % at 5 years. Renal survival was worse in patients aged >65 years than in the younger patients (5-year survival 25.1 % in patients >65 years vs. 50.8 % for those ≤65 years, p < 0.01). The estimated renal survival was better in patients with higher Disease Extent Index (DEI) >6 than in patients with DEI ≤6 (5-year survival 52.1 % vs. 39.4 %, p = 0.04), even though this was not confirmed in multivariate analysis. CONCLUSIONS: The mortality of patients presenting with severe manifestations of AAV remains high despite the use of PLEX. Older age at presentation is associated with worse overall and renal prognosis.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ANCA-asociované vaskulitidy $x mortalita $x terapie $7 D056648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výměna plazmy $x metody $7 D010951
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a čas $7 D013995
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hrušková, Zdenka $u Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. Institute of Immunology and Microbiology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Lánská, Věra $u Statistical Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Lachmanová, Jana $u Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 700 1_
- $a Tesař, Vladimír $u Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- 773 0_
- $w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 18 (20160713), s. 168
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27412443 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20241119085042 $b ABA008
- 999 __
- $a ok $b bmc $g 1300783 $s 1013999
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 18 $c - $d 168 $e 20160713 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
- LZP __
- $a Pubmed-20180515